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http://www.jneuroinflammation.com/content/9/1/199RESEARCH Open AccessPro-inflammatory interleukin-18 increases
Alzheimer’s disease-associated amyloid-β
production in human neuron-like cells
Elina M Sutinen1,2, Tuula Pirttiläˆ, George Anderson3, Antero Salminen1,4 and Johanna O Ojala1,2*Abstract
Background: Alzheimer’s disease (AD) involves increased accumulation of amyloid-β (Aβ) plaques and
neurofibrillary tangles as well as neuronal loss in various regions of the neocortex. Neuroinflammation is also
present, but its role in AD is not fully understood. We previously showed increased levels of pro-inflammatory
cytokine interleukin-18 (IL-18) in different regions of AD brains, where it co-localized with Aβ-plaques, as well as the
ability of IL-18 to increase expression of glycogen synthase kinase-3β (GSK-3β) and cyclin dependent kinase 5,
involved in hyperphosphorylation of tau-protein. Elevated IL-18 has been detected in several risk conditions for AD,
including obesity, type-II diabetes, and cardiovascular diseases as well as in stress.
Methods: We differentiated SH-SY5Y neuroblastoma cells as neuron-like and exposed them to IL-18 for various
times. We examined the protein levels of amyloid-β precursor protein (APP) and its processing products, its
cleaving enzymes, involved in amyloidogenic processing of APP, and markers of apoptosis.
Results: IL-18 increased protein levels of the β-site APP-cleaving enzyme BACE-1, the N-terminal fragment of
presenilin-1 and slightly presenilin enhancer 2, both of which are members of the γ-secretase complex, as well as
Fe65, which is a binding protein of the C-terminus of APP and one regulator for GSK-3β. IL-18 also increased APP
expression and phosphorylation, which preceded increased BACE-1 levels. Further, IL-18 altered APP processing,
increasing Aβ40 production in particular, which was inhibited by IL-18 binding protein. Increased levels of soluble
APPβ were detected in culture medium after the IL-18 exposure. IL-18 also increased anti-apoptotic bcl-xL levels,
which likely counteracted the minor increase of the pro-apoptotic caspase-3. Lactate dehydrogenase activity in
culture medium was unaffected.
Conclusions: The IL-18 induction of BACE-1, APP processing, and Aβ is likely to be linked to stress-associated
adaptations in neurons during the course of normal functioning and development. However, in the course of wider
changes in the aging brain, and particularly in AD, the effects of heightened or prolonged levels of IL-18 may
contribute to the process of AD, including via increased Aβ.
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Alzheimer’s disease (AD) is a neurodegenerative dis-
order, which is characterized particularly by accumula-
tion of amyloid-β (Aβ) peptide in the brain parenchyma
and in the walls of leptomeningeal and parenchymal ves-
sels [1]. Neurofibrillary changes, neuronal loss, synaptic
dysfunction, evidence of oxidative and excitotoxic dam-
age as well as low grade inflammation are also present
in the AD brain [2-4]. Increased Αβ production from
intracellular amyloid precursor protein (APP) metabol-
ism, are believed to initiate the pathogenic processes in
AD. Inflammation also seems to have a role in the ethio-
pathogenesis of AD [4,5], although it is not clear
whether inflammation is a cause, contributor, or second-
ary phenomenon in the disorder [6]. There is also no
clear causal connection between the up-regulation of
pro-inflammatory cytokines and Aβ expression.
Over-expression of pro-inflammatory interleukins 1
and 6 (IL-1, IL-6) has been detected in the AD brain
[7-10]. Pyrogenic IL-1β can induce over-expression of
APP [11] contributing to the generation of neuritic Aβ-
plaques. We have found increased levels of another IL-1
family member, pro-inflammatory IL-18 (interferon-γ-
inducing factor, IL-1γ), in AD brain [12]. Non-pyrogenic
IL-18 has structural similarities with the IL-1 family of
proteins and it can increase production of toxic inflamma-
tory molecules such as IFN-γ [13] and IL-1β [14]. IFN-γ,
via caspase-1 induction, cleaves the pro-forms of IL-1β
and IL-18 to their active mature forms [15] and also
increases levels of IL-18 [16], indicating that up-regulated
IL-18 expression can lead to a harmful vicious cycle of in-
flammation, possibly also in the brain. IL-18 is produced
primarily by activated microglia, but also by astrocytes
and ependymal cells in the central nervous system (CNS)
[17,18]. IL-18 is also detectable in neurons [18,19].
The IL-18 gene is located in the region 11q22.2-22.3
close to the dopamine receptor D2 locus. This region is
near the tip of the long arm of chromosome 11, which
has been reported as a suggestive linkage area for AD in
AD families [20,21]. Further, the IL-18 promoter con-
tains multiple transcription initiation sites [16], and its
polymorphism has been shown to be a risk of late onset
AD [22,23]. However, only single nucleotide polymorph-
isms (SNPs) at positions −137 and −607 have been con-
firmed to have an impact on IL-18 gene activity [24,25].
Individuals with two copies of the IL-18 -607 C or
−137 G allele have been found to have increased odds of
developing AD and these associations were influenced
by the presence of the ApoE E4 alleles, increasing the
risk to develop AD more than five- and four-fold, re-
spectively [23]. These alleles as well as −607 C/-137 G
haplotype are associated with higher expression of the
IL-18 gene and sustained higher levels of the cytokine
[23]. However, Segat et al. (2010) could not findassociation between IL-18 gene promoter polymorphism
(−137 G/C and −607 C/A) and onset of AD [26].
Although no significant increase of circulating cyto-
kines has been detected in AD patients [27], the levels of
IL-18 mRNA in monocyte-macrophages of the periph-
eral blood has been shown to be high in AD-mild
patients, slightly lower in AD-moderate patients, but not
significantly different in AD-severe patients compared to
non-demented age-matched subjects [28]. On the other
hand, a significant increase in production of IL-18 has
been obtained from lipopolysaccharide (LPS)-stimulated
blood mononuclear cells of AD patients, and that was
particular in AD patients carrying the −607 C/C geno-
type of IL-18 promoter. In addition, a significant correl-
ation between IL-18 production and cognitive decline
was apparent in AD patients [27]. Therefore, the in-
crease in the potency of these cells to respond to stimu-
lation by LPS in AD patients may reflect the relative
increase of inflammatory response. This may also occur
in the brain in response to, for example, Aβ, since Aβ42
has been shown to prime at least dendritic cells to
enhanced release of IL-1β, IL-6, and IL-18 [29].
Binding of IL-18 to its receptor in the CNS leads to
activation of the transcription factor NF-κB via a
complex intracellular cascade [30]. Via NF-κB activation,
IL-18 can also activate both Fas and Fas-L promoter
activities [31], which suggests the possibility that IL-18
may be one of the apoptosis-inducing factors contribu-
ting to neurodegeneration during AD progression. IL-18
can also modulate neuronal excitability [32] and IL-18,
like IL-1β and TNF-α, inhibits long-term potentiation
(LTP), a form of neuronal plasticity widely believed to
underlie learning and memory, both in the early p38
mitogen activated protein kinase-dependent (MAPK
p38) phase and the later protein synthesis-dependent
phase [33].
The importance of IL-18 in APP synthesis and proces-
sing is unknown. Interestingly, increased levels of IL-18
have been found in the blood of patients with ischemic
heart disease [34], type-2 diabetes, and obesity [35],
which are all known risk factors for AD [36,37]. The
links between these disorders and AD is not fully under-
stood. IL-18 is also associated with stress [38] and regu-
lates anxiety and fear memory in mice [39]. IL-18 levels
are generally increased in Cushing’s disease patients,
where a significant positive correlation between IL-18
and cortisol is evident [40]. Stress hormones can also in-
crease IL-18 synthesis at least in the layers of zona reti-
cularis and zona fasciculate in the adrenal glands and
peripheral mononuclear cells [40]. IL-18 secretion can
be inhibited, at least in dendritic cells, with the calcium-
channel blocker nifedipine [41].
APP is an integral membrane glycoprotein with
receptor-like structure [42,43], but its physiological
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be fully clarified. Proliferating cells express APP, and it is
detectable at the earliest stages of embryonic develop-
ment [44,45]. As described in Figure 1, the cleavage pro-
ducts of APP can be soluble N-terminal fragments APPα
(sAPPα), APPβ (sAPPβ), as well as Aβ and different
sized C-terminal fragments (CTFs), depending on
whether APP is cleaved by α-, β-, or γ-secretases, and
the cleavage order [46]. In the amyloidogenic Aβ-
producing pathway, APP is first cleaved by transmem-
brane protease β-site amyloid precursor protein-cleaving
enzyme (BACE, β-secretase) [47], localized within Golgi,
endosomes, and plasma membrane [48] and then by
intramembrane γ-secretase. γ-secretase is a multiprotein
complex containing a catalytic site harboring endopro-
teolytically cleaved N- and C-terminal fragments of
presenilin-1 (PS-1), nicastrin, anterior pharynx defective
1 (Aph1), and presenilin enhancer 2 (Pen-2). This
complex forms in the Golgi/trans-Golgi network [49]. In
the non-amyloidogenic pathway, APP is cleaved by
α-secretase. A Disintegrin and Metalloproteinase
domain-containing proteins 9, 10, and 17 (ADAM9,
ADAM10, ADAM17/TACE; TNF-α convertase) can
function as an α-secretase [50].Figure 1 Processing of APP by secretases. APP (85 kD) can be
cleaved by α-secretase (α). This generates soluble APPα (sAPPα;
76 kD) and C-terminal fragment C83 (CTFα; ~9 kD). In the
amyloidogenic pathway, APP is cleaved by β-secretase (β) to
generate of sAPPβ (74 kD) and the C-terminal fragment C99 (CTFβ;
approximately 11 kD), which in turn is cleaved by γ-secretase (γ) to
generate amyloid-β (Aβ; approximately 4.5 kD) and amyloid
intracellular domain AICD (CTFγ; approximately 6 kD). AICD is also
produced when C83 is cleaved by γ-secretase [46]. This cleavage
generates also P3 (approximately 2.6 kD). The N-terminal fragment
of sAPPβ can be cleaved by an as yet unconfirmed protease as N-
APP (approximately 30 kD) and sAPP55 (approximately 45 kD) [51].
Arrowheads indicate caspase-3 cleavage site of APP amino acids (aa)
[52]. WO-2 and 22C11 are used in this study as antibodies (ab) to
detect the shown fragments. The dotted line pentagons indicate the
binding sites of the antibodies.The amyloidogenic processing of APP seems to be at
least partially regulated by its Thr668 phosphorylation
(numbering for APP695 isoform) [53,54], including by
the cyclin-dependent kinase 5 (Cdk5)/p35 complex [55].
Previously we showed that IL-18 increases not only pro-
tein levels of Cdk5/p35 but also glycogen synthase
kinase-3β (GSK-3β) [19]. GSK-3β seems to be regulated
at least partially by the Fe65/AICD complex [56]. GSK-
3β phosphorylates and regulates the levels and function
of PS-1 [57,58].
In this study, we examined the relationship of IL-18
on APP processing and Aβ formation in vitro in neuron-
like differentiated SH-SY5Y-neuroblastoma cells. We
found that IL-18 increased production of APP and its
phosphorylation at Thr668. Further, IL-18 increased the
amyloidogenic processing of APP by increasing expres-
sion of BACE-1 (70 kD) and levels of the 34 kD N-
terminal fragment of PS-1 (NTF), contributing to a
functional γ-secretase. Expression of ADAM10 was very
low in these cells, thus definite conclusions as to the im-
pact of IL-18 cannot be made. Increased Aβ production
after IL-18 administration was detectable in cell lysate,
and this was prevented by the simultaneous application
of IL-18 binding protein (IL-18 bp). Increased Aβ pro-
duction was also detectable in normal human astrocytes
(NHA) after the addition of IL-18. IL-18 increased cellu-
lar level of bcl-xL but had only a minor impact on cellu-
lar caspase-3 and did not affect lactate dehydrogenase
(LDH) activity in culture medium. Some comparison
studies were done with IL-1β, and the results were
somewhat in line with the IL-18 results, although the
timeframe of changes seemed to be different.
Materials and methods
Cell culture
The work was done with commercially available cells and
products only. SH-SY5Y neuroblastoma (DSMZ; Braun-
schweig, Germany) were maintained in 50% Dulbecco’s
medium (DMEM; BioWhittaker/Lonza) containing 4.5 g/L
glucose and 50% Opti-MEMW Reduced Serum Medium
with GlutaMAX™ (Invitrogen). Mixture was supplemented
with 5% heat-inactivated fetal bovine serum (iFBS;
HyClone/Pierce; Logan, UT, USA), 1 mM L-glutamine
(Lonza), 100 U/mL penicillin and 10 μg/mL streptomycin
(Lonza). The cells were plated as 105 cells/well into the
12-well plates (Nunc™; Roskilde, Denmark) in DMEM
containing the supplements. The cells were differentiated
for 3 days with 10 μM all-trans retinoic acid (ATRA;
Sigma-Aldrich; St Louis, MO, USA) treatment, which was
followed by 4 days of 50 ng/mL human recombinant
brain-derived neurotrophic factor (BDNF; Alomone Labs,
Jerusalem, Israel) treatment in DMEM with supplements
but without iFBS. Normal human astrocytes (NHA;
Lonza) were plated as 6 × 104 cells/well in 12-well plates
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glucose, and supplemented with 10% iFBS, 2 mM L-
glutamine, antibiotics, and 1× AGMTM SingleQuotsW
(Lonza). The NHA experiments were initiated 2 days
after plating.
Treatments
Recombinant human IL-18 (IL-18; MBL, Naka-ku Na-
goya, Japan) was added to the culture medium as
described [19]. IL-18 binding protein (IL-18 bp; Recom-
binant Human IL-18BPa/Fc Chimera; R&D Systems) was
added at 0.5 μg/mL to the pre-made IL-18 (100 ng/mL)
medium, and the mixture was added immediately to the
cultures. BDNF was present in SH-SY5Y cultures during
the IL-18 treatments. IL-1β (Biosource/Invitrogen) was
used at 10, 20, 50, 100, 150 ng/mL in some comparison
SH-SY5Y experiments. NHA cells were treated with
100 ng/mL IL-18, IL-1β (Biosource/Invitrogen), or
Interferon-γ (Biosource/Invitrogen) for 6 h or exposed to
1 mM H2O2 (J.T.Baker; Deventer, Holland) in DMEM for
10 min, after which fresh culture medium was added for
6 h. Treatments were done without iFBS and AGMTM
SingleQuotsW supplementation. Amyloid β-Protein (1–42)
was purchased from Bachem (Bachem AG, Bubendorf,
Switzerland). Some of the SH-SY5Y experiments were
photographed just before harvesting by using Nikon
Ecclipse TE300 inverted tissue culture microscope (object-
ive Plan Fluor 20×/0.45) and Nikon Coolpix 995 camera.
After the incubations, culture media were collected and
the cells were lysed with M-PER lysis buffer (Pierce/
Thermo Fisher Scientific Inc., Rockford, IL, USA) contain-
ing Protease Inhibitor Mix (GE Healthcare).
Protein, LDH, and ELISA measurements
Protein levels were estimated with the DC protein assay
kit (Bio-Rad Laboratories, Hercules, CA, USA) accord-
ing to manufacturer’s protocol. LDH activity was mea-
sured from SH-SY5Y culture medium with CytoTox 96W
Nonradioactive Cytotoxicity Assay (Promega). Aβ forms
were examined from cell lysate and culture medium by
using Amyloid Beta x-40 and Amyloid Beta x-42 Chemi-
luminescent ELISA kits (Covance/Nordic Biosite)
according to manufacturer’s instructions.
Immunoblotting
Equal protein amounts (20 μg or 35 μg) from lysate and
equal medium volumes (65 μL) were separated in 12.5%
gels in sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis and the proteins were transferred to a
Hybond P membrane (GE Healthcare). Full-Range and
Low-Range Rainbow Molecular Weight Markers (GE
Healthcare) as well as NovexW Sharp Prestained Protein
Standard (Life Technologies™) were used for the detec-
tion of the correct molecular weight targets.The following antibodies were purchased from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA): BACE-1
(61-3E7; sc-33711), PS-1 (H-70; sc-7860), Pen-2 (FL-101;
sc-32946), Aph-1 (H-50; sc-98469), nicastrin (N-19; sc-
14369), ADAM10 (S-10; sc-16523), Fe65 (H-260; sc-
33155), p-β-Amyloid (Thr 668) (sc-101632), caspase-3
p11 (K-19; sc-1224), and bcl-xL (S-18; sc-634). Anti-Aβ[4-
10]-Antibody (WO-2) was purchased from the Genetics
Company, Inc. (Schlieren, Switzerland) and anti-
Alzheimer precursor protein A4 antibody (22C11) from
Chemicon/Millipore. Anti-Actin (H-196; sc-7210; Santa
Cruz Biotechnology, Inc.) and anti-α-Tubulin (clone B-5-
1-2, mouse Ascites fluid; Sigma-Aldrich) were used as
loading controls.
The membranes were blocked with 3% non-fat milk
(Valio; Finland) in phosphate buffered saline (PBS; pH
7.5)/0.05% Tween-20 (Sigma-Aldrich) for 1 h, and the
antibodies purchased from Santa Cruz Biotechnology,
Inc. were used as 1:300 or 1:400 dilutions and Tubulin
as 1:8000 as described [19]. When 22C11 and WO-2
antibodies were used, the membranes were blocked with
5% non-fat milk and 0.25% bovine serum albumin, frac-
tion V (Roche Diagnostics; Mannheim, Germany) in
Tris-buffered saline (pH 7.6; TBS)/0.05% Tween-20, at
room temperature for 30 min, after which the antibody
(0.75 μg/mL) was added. Incubations were done over-
night at +4 °C. After all antibody incubations, the mem-
branes were washed as described [19].
For detection, the membranes were incubated with
ECL™ donkey anti-rabbit IgG F(ab’)2 peroxidase-linked de-
tection antibody (GE Healthcare), ECL™ anti-mouse IgG
peroxidase-linked species-specific whole antibody (from
sheep) (GE Healthcare) or bovine anti-goat IgG-HRP,
mouse/human adsorbed (sc-2384; Santa Cruz Biotech.)
detection antibodies at room temperature for 1 to 1.5 h.
Immobilon Western Chemiluminescent HRP Substrate
(Millipore; Billerica, MA, USA) was added to the washed
membrane and Fujifilm Super RX (Fuji Photo Film Co.,
Ltd) was used for the documentation. The detected bands
were quantitied with a MCID M5-image analysis system
(Imaging Research Inc.; Ontario, Canada).
The membranes were stripped after the detection by
washing four times with TBS/0.1% Tween-20, incubating
in stripping buffer (62.7 mM Tris, 2% SDS and 0.7% β-
mercaptoethanol; pH 6.8) slightly shaking at +50 °C, fol-
lowed by washing six times with TBS/0.1% Tween-20.
The membranes were used three to five times.Statistical analysis
The numerical results were analyzed with Mann–Whitney
U-Test (M-W) and Student’s t-Test (t-Test). The experi-
ments were independently repeated as indicated and the
number (n) of controls and treatments were equal.
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IL-18 treatment increased protein levels of BACE-1, NTF of
PS-1, and Fe65
First we examined the presence of IL-18 receptor (IL-
18R) and IL-18 bp in differentiated SH-SY5Y neuro-
blastoma cells. Our cells expressed IL-18R and its
protein levels were unaltered by IL-18 treatments
(data not shown). IL-18 bp was not detectable at the
protein level (data not shown). We also detected
added correct size IL-18 in the cell lysate even in 72-h
treated cells indicating its stability (Figure 2H). Our
findings are in line with Sallmon et al. (2010), who
have previously shown that SH-SY5Y neuroblastoma
cells express IL-18R and IL-18 bp, and when differen-
tiated with ATRA, also IL-18, whereas the level of IL-
18 bp reduces after ATRA treatment [59].
We examined how IL-18 affects protein levels of par-
ticularly BACE-1 and PS-1 in neuron-like differentiated
SH-SY5Y neuroblastoma. IL-18 (100 ng/mL) increased
the protein levels of BACE-1 (70 kD) at 24 h (131%,Figure 2 Levels of APP cleaving enzymes in neuron-like differentiated
100, or 150 ng/mL) for described times. (A) BACE-1 (70 kD) increased after
the impact of IL-18 was suppressed with IL-18 bp (IL-18 100 ng/mL+ IL-18B
increased protein level of NTF of PS-1 (34 kD) compared to the untreated c
in IL-18 treated cells. The bands above are likely partially formed γ-secretas
expression of Pen-2 at 72 h. Arrowheads indicate bands in PS-1 and Pen-2
(D) Fe65 (77 kD) increased in 24-h treated cells. (E) Loading control actin fo
(F) Aph-1 (29 kD) and nicastrin increased in 24-h IL-18 treated cells. The pro
superimposing. (G) Expression of ADAM10 was generally very low (60 kD a
presence of recombinant IL-18 in 72-h IL-18 treated SH-SY5Y lysate. Actin a
NTF, N-terminal fragment of PS-1; RcIL-18, recombinant IL-18.P <0.000) and 72 h (68%, P <0.000) time points
(Figure 2A(a),(b); Table 1), and the impact of IL-18
was suppressed with simultaneous treatment with
0.5 μg/mL IL-18 bp (Figure 2A(b), last lane). The ef-
fect of IL-18 on BACE-1 was also concentration (50–
150 ng/mL) dependent particularly in 24-h treated
cells (data not shown). Protein levels of NTF of PS-1
(34 kD) were also increased by IL-18 in a concentration
dependent manner (50–150 ng/mL) (Figure 2B). The in-
crease in NTF was significant at 6 h in IL-18 treated
cells (192%, P 0.017) (Table 1). The 53 kD precursor of
PS-1 was significantly increased later, at 48 h, following
IL-18 addition (26%, P 0.068 (M-W), P 0.050 (t-Test))
(Table 1) with the increase at 24 h approaching signifi-
cance (67%, P 0.058 (t-Test)) (Table 1).
Since Pen-2 is required for the endocytic processing of
PS-1 (53 kD) and activation of the γ-secretase complex
[60], we investigated its protein levels following IL-18
addition. Pen-2 interacts with NTF but not with CTF of
PS-1 [61]. However, Pen-2 (12 kD) was generally hardlySH-SY5Y neuroblastoma cells. The cells were treated with IL-18 (50,
100 ng/mL IL-18 treatment compared to the untreated control (a), (b);
Pa 0.5 μg/mL) (b). (B) IL-18, in a concentration-dependent manner,
ontrol. Protein synthesis of PS-1 (53 kD) increased slightly only at 24 h
e complexes including NTF of PS-1. (C) IL-18 treatment increased
films co-localized when the Pen-2 and PS-1 films were superimposed.
r the results B to D, which were obtained from the same membrane.
bings are from the same membrane and arranged according to the
ctive form, 80 kD partially processed, 100 kD precursor). (H) The
nd Tubulin were used as loading references. Ctrl, untreated control;
Table 1 Mean percentage alteration of protein levels of IL-18 treated targets compared to untreated ones, analyzed
from western blots
6 h 24 h 48 h 72 h
APP, approximately 100 kD Mean %± SEM 74.9 ±17.2 19.3 ±9.9 56.5 ±12.4 −3.0 ±10.1
n 20 31 30 31
t-Test, P <0.000a 0.062 <0.000a 0.769
M-W, P 0.001a 0.809 <0.000a 0.243
BACE-1, approximately 70 kD Mean %± SEM 35.1 ±29.7 131.1 ±35.4 39.1 ±25.1 67.8 ±21.5
N 11 20 18 19
t-Test, P 0.107 0.002b 0.310 0.006b
M-W, P 0.700 <0.000a 0.543 <0.000a
PS-1, approximately 34 kD Mean %± SEM 191.9 ±80.7 22.6 ±28.4 26.5 ±25.9 5.4 ±16.0
n 7 17 16 18
t-Test, P 0.055 0.322 0.323 0.741
M-W, P 0.017c 0.734 0.519 1.000
PS-1, approximately 53 kD Mean %± SEM 121.9 ±68.7 67.0 ±32.9 26.0 ±12.3 −18.9 ±10.4
n 9 18 18 18
t-Test, P 0.114 0.058 0.050c 0.087
M-W, P 0.203 0.543 0.068 0.543
PS-1, approximately 100 kD Mean %± SEM 79.7 ±55.9 51.4 ±19.2 27.8 ±16.4 8.1 ±12.1
n 10 19 19 20
t-Test, P 0.106 0.138 0.767 0.247
M-W, P 0.192 0.016c 0.106 0.377
bcl-xL, approximately 30 kD Mean %± SEM 20.7 ±36.6 −6.3 ±11.2 17.7 ±19.5 23.5 ±8.7
n 5 15 14 14
t-Test, P 0.602 0.582 0.381 0.018c
M-W, P 0.577 0.319 0.034c 0.039c
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kD band, but at the highest concentration used (150 ng/
mL) IL-18 appeared to increase its protein level at 72 h
(Figure 2C). However, increased levels of Pen-2 antibody
reactivity was found around the 80 kD band in IL-18
treated cells (Figure 2C,F). Aph1 and Nicastrin showed
also some increase in 24-h IL-18 treated cells
(Figure 2 F). Nevertheless, since the active γ-secretase
complex includes the NTF and CTF (18.5 kD) of PS-1,
Pen-2 (interacts with NTF), Aph1 (29 kD; interacts with
CTF) and nicastrin (75 kD as unglycosylated), the high
molecular weight bands shown in Figure 2B, C, and F
are likely partially formed γ-secretase complexes. The
approximate 100 kD band cluster (Figure 2B) was mea-
sured and its increase was 51% (P 0.016 (t-Test))
(Table 1) at 24 h after the IL-18 treatments.
Due to our earlier findings with GSK-3β [19], we
also examined protein levels of Fe65. Fe65 (77 kD)
interacts with AICD (Figure 1) and this complex regulatesexpression of GSK-3β [56], which in turn can regulate for
instance the levels and function of PS-1 [57,58]. Protein
levels of Fe65 were increased at 24 h in IL-18 treated cells,
at IL-18 concentrations of 100 or 150 ng/mL (Figure 2D).
Expression of ADAM10, one of the α-secretases, was
very low in our cells (Figure 2G) suggesting that it is not
the main α-secretase in SH-SY5Y cells. Other α-secretases
were not examined. However, it seemed that IL-18 treat-
ment slightly decreased the 60 kD active form of
ADAM10 levels when compared to actin (Figure 2G), but
this result requires confirmation with other methods.
IL-18 treatment increased levels of APP, altered its
processing, and increased Aβ levels in SH-SY5Y cells
IL-18 increased protein level of APP (75%, P 0.001)
(Figure 3A, Table 1) as well as its phosphorylation at the
Thr668 site (Figure 3B) in 6-h treated SH-SY5Y cells. In-
crease of APP was detectable also at the 48-h time-point
(57%, P <0.000) (Table 1).
Figure 3 Expression of APP products in differentiated SH-SY5Y neuroblastoma cells and in normal human astrocytes. The differentiated
SH-SY5Y-cells were treated with IL-18 (100 ng/mL) without or with IL-18 bp (0.5 μg/mL) for described times. IL-18 treatment increased (A) APP
synthesis during 6-h and 48-h treatment and (B) Thr668 phosphorylation of APP during 6-h treatment in SH-SY5Y cells. IL-18 treatment also
increased the protein levels of (C) C99 (approximately 11 kD) and Aβ (approximately 4 kD) (WO-2 antibody), the BACE-1 and γ-secretase cleavage
products of APP in (a) differentiated SH-SY5Y cells but also in (b) normal human astrocytes. When examined from the same SH-SY5Y culture
medium, (D) total sAPP was only slightly increased by the IL-18 treatment (22C11 antibody detects sAPPα (76 kD) and sAPPβ (74 kD)). When WO-
2 antibody was used (detects only sAPPα) for the same samples, the protein level of sAPPα was less in IL-18 treated culture medium, compared
to untreated control (Ctrl), showing indirectly the increase in sAPPβ production by IL-18 in SH-SY5Y medium.
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ate, 100 ng/mL IL-18, for 24 or 72 h, increased the pro-
tein levels of APP cleavage products: Aβ (approximately
4 kD) and C99 (approximately 11 kD), as well as faintly
expressed bands at approximately 76 kD (possibly
sAPPα) and approximately 46 kD (possibly sAPP cleav-
age product (Figure 1)) as shown in Figure 3C(a). The
effect of IL-18 was abolished with simultaneous treat-
ment with 0.5 μg/mL of IL-18bpA (Figure 3C(a)), which
is the predominant IL-18 bp form. Interestingly, IL-18
also increased levels of C99 and Aβ in NHA-cells treated
for 6 h. IFN-γ (100 ng/mL) and 1 mM H2O2 (10 min in-
sult) had a similar effect, whereas IL-1β had no impact
(Figure 3C(b)). Nevertheless, in both cell types, the pro-
duced type of Aβ was mainly Aβ40 although some Aβ42was also produced (ratio: approximately 3 Aβ42/100
Aβ40). The total amount of Aβ40 (cell lysate and
medium) was approximately 260.7 pg in 105 SH-SY5Y
cells, treated with IL-18 for 72 h vs. approximately
229.9 pg in 105 untreated cells (13.3%, SEM ±0.81; n= 3;
P 0.004 (t-Test)). However, the Aβ40 estimate is very
crude, due to the pronounced background in ELISA.
Aβ42 levels were estimated to be approximately 7.14 pg/
mL from the same samples, but no clear difference be-
tween IL-18 treatment and control were apparent par-
tially due to the sensitivity limits of the ELISA kit.
In SH-SY5Y culture medium, the ratio of sAPPα and
sAPPβ showed alteration during the IL-18 treatment
when compared to the untreated control (Figure 3D). As
indirectly shown (binding regions for the antibodies are
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portion of sAPPβ from total sAPP, whereas in untreated
control cell medium, the amount of sAPPα was greater,
supporting the increased β-amyloidogenic processing of
APP.
IL-1β altered the expression levels of BACE-1, PS-1 and
APP but differently to IL-18
We treated differentiated SH-SY5Y cells also with IL-1β
(10- to 150 ng/mL) as reference for IL-18. Since our
main interest was IL-18, the number of repeats of these
experiments was not enough to do proper statistics.
However, changes were apparent mainly with 50 ng/mL
or 100 ng/mL of IL-1β whereas 10 or 20 ng/mL was too
low for our targets and 150 ng/mL seemed to be harm-
ful to the cells. Nevertheless, the main increase of
BACE-1 appeared later than with IL-18, at 48 h when
50 ng/mL of IL-1β was used (Figure 4A). The impacts of
IL-1β on PS-1 were also less than that of IL-18
(Figure 4B). IL-1β treatment concentration dependently
also increased APP levels during 6-h treatment
(Figure 4C) and Aβ became apparent (Figure 4D) at
24 h. Similar kind of results were gained when IL-1β
was used as 100 ng/mL. However, IL-1 is tightly regu-
lated and we did not examine the expression levels
for instance of IL-1 receptor (IL-1R), IL-1 receptorFigure 4 IL-1β treated differentiated SH-SY5Y cells. The cells were trea
(70 kD) increased particularly in 48-hr IL-1β treatment (50 ng/mL) compare
increased protein level of NTF of PS-1 (34 kD), whereas protein synthesis of
compared to untreated control. (C) IL-1β treatment increased protein level
treatment increased slightly Aβ production. (E) Bcl-xL reduced in 6-h IL-1β
control; NTF, N-terminal fragment of PS-1.antagonist (IL-Ra), or IL-1 receptor accessory protein
(IL-1RAcP). The low expression level of, for example,
IL-1RI or IL-1RAcP may cause the poor response of
SH-SY5Y to IL-1, whereas high expression of IL-1Ra
or soluble IL-1RII, shed from the plasma membrane
by BACE-1 [62], may inhibit IL-1 binding to its func-
tional receptor and thus reducing the response of the
cells.
IL-18 treatment increased cellular level of bcl-xL but had
only a minor impact on cellular caspase-3 and did not
affect LDH activity in culture medium
Since IL-18 treatment increased Aβ levels in cell lysate,
and binding of IL-18 to its receptor complex can lead to
activation of JNK and MAPK p38 [63], in turn activating
pro-apoptotic signaling pathways [64], we examined ex-
pression of pro-apoptotic caspase-3 and anti-apoptotic
bcl-xL from the cell lysate as well as LDH activity from
the culture medium.
Expression of pro-caspase-3 (32 kD) was reduced at
6 h in IL-18 treated cells, but increased at 72 h
(Figure 5A). However, the protein level of caspase-3 (ap-
proximately 58 kD; approximate size of an active tetra-
mer complex), showed only a minor increase at 72 h
(Figure 5A). IL-18 also increased bcl-xL levels at 72 h
(23%, P 0.039) (Table 1) in a concentration dependentted with IL-1β (50, 100, or 150 ng/ mL) for described times. (A) BACE-1
d to the untreated control. Actin was used as loading control. (B) IL-1β
precursor PS-1 (53 kD) decreased in 6-h or 24-h IL-1β treated cells
s of APP concentration dependently in 6-h treated cells. (D) IL-1β
treated cells but increased in the final 72-h time point. Ctrl, untreated
Figure 5 Protein levels of indicators of apoptosis in
differentiated SH-SY5Y cells. The cells were treated with IL-18
(100 ng/mL) for described times. IL-18 (A) decreased pro-caspase-3
(approximately 32 kD) at 6 h, but increased its level in 72-h treated
cells. The approximate 58 kD form, which is likely the active form
composed of two 12 and 17 kD fragments of caspase-3, increased
very slightly in 72-h treated cells. (B) Bcl-xL, which inhibits activation
of caspases, was slightly reduced at 6-h IL-18 treated cells but
induced in 72-h timepoint. Actin was used as a loading control.
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in culture medium even when IL-18 was used at 100 or
150 ng/mL for 72 h with or without 1 μM Aβ42 addition
(data not shown). The survival of IL-18 or IL-1β treated
with or without Aβ42 addition and untreated control
cells showed no significant difference either, even after
72-h incubation (Figure 6) in all experiments (n= 6).
However, Aβ42 treatment caused clustering of the cells,
particularly when IL-18 was included (Figure 6E). Fur-
ther studies with longer incubation time will be required
to test for the differences, including vacuolization.Discussion
We found that IL-18 can increase production of APP
and its Thr668 phosphorylation in neuron-like differen-
tiated human SH-SY5Y cells. IL-18 also increased amy-
loidogenic processing to Aβ by inducing expression of
BACE-1 and NTF of PS-1, part of the functional γ-
secretase complex. IL-18 slightly increased protein levels
of the anti-apoptotic bcl-xL and apoptotic caspase-3, but
had no effect on LDH release.The IL-18 increase in APP protein levels was an early
response. APP, a member of the gene family including
Amyloid Precursor-Like Proteins APLP1 and APLP2,
exists as several distinct isoforms arising by alternative
splicing of a single gene. The predominant neuronal
APP isoform is APP695 [65]. APP has importance in
cortical development, and mice that lack all three APP
family members exhibit early postnatal lethality and
neuroanatomical abnormalities [66]. APP may partici-
pate in regulation of the cell cycle during embryonic de-
velopment [45], and seems required for correct neuronal
migration [67]. APP forms are also associated with neur-
ite outgrowth [68], with the cytoplasmic domain of APP
interacting with the cytosolic adapter Fe65 in the regula-
tion of neurite branching [69]. APP can also be rapidly
transported down the axon to the synapses and, like Aβ,
may have importance in the formation of synapses [70]
and their functional regulation [71]. Thus, IL-18 may en-
hance neurite and synapse formation, which is in line
with our earlier observations [19].
The IL-18 induced increase in APP Thr668 phosphory-
lation was an early response. APP has eight potential
phosphorylation sites in its cytoplasmic domain [72], with
its phosphorylation increasing in parallel with neuronal
differentiation, especially at the time of neurite outgrowth
[43]. Further, phosphorylated APP is distributed in neu-
rites, particularly in growth cones [43]. Whereas GSK-3β
can phosphorylate the cytoplasmic domain of the APP at
its Thr743 [73], Cdk5, GSK-3α, and JNKs can mediate
phosphorylation of N- and O-glycosylated APP at its
Thr668 site [55,74]. Thr668 phosphorylation is linked to
neurite extension and anterograde transport of vesicular
cargo [75]. As such IL-18, via its modulation of APP, will
impact on wide cellular processes, including synaptic plas-
ticity. Further, Thr668 phosphorylation of APP facilitates
its BACE-1 cleavage [54] aiding the initiation of the amy-
loidogenic pathway (Figure 1).
IL-18 also increased protein levels of BACE-1 (ap-
proximately 70 kD). BACE-1 is essential for cognitive,
emotional, and synaptic functions [76]. Electrophysiolo-
gically, BACE-1-deficient neurons exhibit subtle altera-
tions in the steady-state inactivation of voltage-gated
sodium channels [77]. BACE-1 knockout mice in turn
displayed significant neonatal lethality, suggesting an es-
sential function. BACE-1 is highly expressed at the time
when peripheral nerves become myelinated and is
needed for neuregulin processing, with loss of BACE-1
inducing hypomyelination [78], suggestive of a role for
IL-18 and BACE-1 in multiple sclerosis [79]. Further, ex-
perimental traumatic brain injury in rats also stimulates
BACE-1 expression, production, and activity [80]. Thus,
increased expression of BACE-1 by IL-18 suggests that
BACE-1 and Aβ may be needed for synapse formation
and sodium-voltage gate regulation during development
Figure 6 The appearance of differentiated SH-SY5Y cells after IL-18 or IL-1β treatments with or without amyloid-β42 addition. (A)
Differentiated untreated control cells. (B) The cells were treated with IL-18 (100 ng/mL) or (C) with IL-1β (50 ng/mL) for 72 h. IL-1β exposed cells
seemed to be more vacuolized than the control cells or IL-18 treated cells. The cells were treated (D) with 1 μM Aβ42 only, (E) with IL-18
(100 ng/mL), and 1 μM Aβ42 for 72 h, (F) with IL-1β (50 ng/mL) and 1 μM Aβ42 for 72 h. The arrowheads indicate the clustering of the cells.
Magnification 200x, bar 10 μm as shown in (A).
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regulation of hypomyelination in neurodegenerative dis-
orders requires further investigation.
The impact of IL-18 on PS-1 was not as pronounced as
on APP and BACE-1. IL-18 increased precursor PS-1 (53
kD) moderately as well as Pen-2 (12 kD) very slightly,
but later than the increase in APP and its Thr668 phos-
phorylation. The levels of endoproteolytic NTF of PS-1
significantly increased approximately at the time of the
rise in APP and BACE-1. This suggests that the immedi-
ate interaction of Pen-2 with the PS-1 precursor leads to
the endoproteolytic cleavage of PS-1 and to the forma-
tion of a functional γ-secretase complex. Despite this, in
our experiments, the limiting factor for Aβ production
seemed to be γ-secretase, since the level of C99 fragment
(Figure 1) was generally higher than that of Aβ indicating
the need of an additional stimulus for activation of γ-
secretase. It has been shown that absence of PS-1 and
PS-1/PS-2 strongly reduces Pen-2, which is further
reduced when nicastrin level is low [81]. On the other
hand, down-regulation of Pen-2 decreased PS levels and
impaired nicastrin maturation, resulting in deficient γ-
secretase complex formation. Thus the components of
the γ-secretase complex are expressed in a coordinated
manner [81]. Nevertheless, γ-secretase has an essential
role in development and neurogenesis [82,83], but it isalso a promiscuous aspartyl protease, which can cleave
numerous type-I transmembrane proteins after their
large ectodomain are shed [84,85]. The substrates of γ-
secretase include proteins involved in neurite outgrowth
and synapse formation as well as cell fate decisions and
adhesion [84]. Presenilin has also other functions inde-
pendent of γ-secretase, including roles in organelle trans-
port and turnover, Akt-ERK signaling, cytoskeletal
dynamics, and as a calcium leak channel in the endoplas-
mic reticulum [86].
The IL-18 induction of Aβ was abolished by the simul-
taneous treatment with IL-18 bp. Interestingly, IL-18 also
increased Aβ production in normal human astrocytes
similar to the effects of IFN-γ and H2O2, whereas IL-1β
had only a very minor impact. The normal function of
astrocytic Aβ is not understood, although glia, which are
more abundant than neurons, may substantially contrib-
ute to the Aβ-plaque formation when the amyloidogenic
cleavage system is activated in astrocytes. The Aβ-
plaques are primarily made of Aβ peptides 1 to 40 and 1
to 42, both forms elevated in AD, but particularly Aβ42
is correlated with AD cognitive decline [87-89]. However,
Aβ is also produced as part of normal metabolism and
can be detected in the blood [90] and cerebrospinal fluid
[91]. Physiological level of Aβ may regulate synaptic
function and keep neuronal hyperactivity in check by
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cells, Aβ is toxic [93,94] and can disrupt synaptic func-
tion [92]. Thus IL-18 in both neurons and astrocytes may
contribute to enhancing Aβ effects, both positive and
negative, particularly in the aged neurons.
Alterations in APP processing were also apparent in
the culture medium. The ratio of sAPPβ to sAPPα
increased following IL-18 treatment. sAPPα, reduced in
familial and sporadic AD patients [95], has been impli-
cated in neurite outgrowth [96], neuroprotection [97],
neurotrophism and adult neurogenesis [98], axonal
transport [99], synaptic function [92], and transcriptional
regulation [100]. sAPPβ in turn can robustly drive neural
differentiation of human embryonic stem cells [101].
Thus, IL-18, via sAPPβ to sAPPα ratio will modulate
neural differentiation and survival functions.
The CTFs of APP, increased in AD patients’ brains,
may be more neurotoxic than Aβ. These CTFs have
been shown to impair calcium homeostasis as well as
learning and memory through blocking LTP [102]. The
cleavage of the C99 fragment through residues 48 to 50
by γ-secretase generates AICD59 (Figure 1), which can
interact with several binders, including the phosphotyro-
sine interaction domain of Fe65 [72] to form a transcrip-
tionally active complex. We showed that IL-18 increases
protein level of Fe65 (approximately 77 kD). However,
the phosphorylation of Thr668 in AICD is essential for
its binding to Fe65 and to nuclear translocation, where it
forms a ternary complex with transcription factor CP2/
LSF/LBP1. This complex functions as a transcriptional
activator for GSK-3β, APP, and BACE, as well as for
transgelin, α2-actin, IGFBP3, and Aβ degrading neprily-
sin [103]. In our previous study [19] we found increased
levels of GSK-3β after IL-18 treatments. Whether Fe65
mediated this remains to be determined. GSK-3β also regu-
lates the CTF of PS-1 through its Ser397 phosphorylation
[57], likely to decrease γ-secretase activity and altering the
balance of C99 and Aβ.
The early phase of Aβ42-induced cytotoxicity in neur-
onal cells is associated with vacuole formation and en-
hancement of exocytosis [104]. A suggestion of increased
vacuolization in IL-18 treated cells was apparent at the
final time point. Since caspase-3 activation can be induced
by Aβ leading to apoptosis [105], we also examined pro-
tein levels of caspase-3. Protein level of pro-caspase-3 (32
kD) altered time-dependently indicating its processing to
the functional tetrameric complex. On the other hand, the
tetrameric 58 kD form of caspase-3 increased only very
modestly in IL-18 treated cells. Although caspase-3 is
implicated in APP processing into amyloidogenic frag-
ments with the accumulation of caspase-cleaved APP evi-
dent in the early phases of AD [52], the role of caspase-3
in APP processing when the amyloidogenic processing
machinery is activated is unknown.Bcl-xL is a negative regulator of caspase-3 activation
in immature neurons during development [106].
Caspase-3 and bcl-xL also seem to have epistatic and in-
dependent functions in developmental programmed cell
death [107]. Bcl-xL protects neurons from Aβ neurotox-
icity, as shown in bcl-xL over-expressing SH-SY5Y cells
[108]. In our studies, protein levels of bcl-xL were
slightly increased at the final time-point by IL-18 treat-
ment, suggesting a counteracting of caspase-3 apoptotic
processes.
In conclusion, the present study shows that IL-18
increases APP expression and phosphorylation, which
precede increased BACE-1 levels. The IL-18 induction
of BACE-1, APP processing and Aβ is likely to be linked
to stress associated adaptations in neurons and glia dur-
ing the course of normal functioning and development.
Further, in our cell culture system the limiting factor for
Aβ production seemed to involve PS-1, the activation of
which may require more enhanced expression of Pen-2
or other factors, influenced by other mediators than IL-
18. However, in the course of wider changes in the aging
brain, and particularly in AD brain, the effects of heigh-
tened or prolonged levels of IL-18 may contribute to the
process of AD, including via increased Aβ.
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